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Abstract
Background: In humans, muscle-specific nicotinergic acetylcholine receptor (AChR) is a transmembrane protein
with five different subunits, coded by CHRNA1, CHRNB, CHRND and CHRNG/CHRNE. The gamma subunit of AChR
encoded by CHRNG is expressed during early foetal development, whereas in the adult, the γ subunit is replaced by
a ε subunit. Mutations in the CHRNG encoding the embryonal acetylcholine receptor may cause the non-lethal
Escobar variant (EVMPS) and lethal form (LMPS) of multiple pterygium syndrome. The MPS is a condition characterised
by prenatal growth failure with pterygium and akinesia leading to muscle weakness and severe congenital contractures,
as well as scoliosis.
Results: Our whole exome sequencing studies have identified one novel and two previously reported homozygous
mutations in CHRNG in three families affected by non-lethal EVMPS. The mutations consist of deletion of two
nucleotides, cause a frameshift predicted to result in premature termination of the foetally expressed gamma subunit
of the AChR.
Conclusions: Our data suggest that severity of the phenotype varies significantly both within and between families
with MPS and that there is no apparent correlation between mutation position and clinical phenotype. Although
individuals with CHRNG mutations can survive, there is an increased frequency of abortions and stillbirth in their
families. Furthermore, genetic background and environmental modifiers might be of significance for decisiveness of
the lethal spectrum, rather than the state of the mutation per se. Detailed clinical examination of our patients further
indicates the changing phenotype from infancy to childhood.
Background
Multiple pterygium syndromes (MPS) comprise a group
of multiple congenital anomalies of the skin, muscles
and skeleton [1, 2]. It is characterised by prenatal growth
failure with webbing (pterygium) of the skin present in
multiple areas and a lack of muscle movement (akinesia)
leading to muscle weakness and severe congenital
contractures (arthrogryposis), and scoliosis. The MPS is
a clinically and genetically heterogeneous disorder but it
is traditionally divided into lethal (LMPS, OMIM
253290), which is fatal before birth or very soon after
birth, and non-lethal (Escobar variant, EVMPS, OMIM
26500) MPS types [3]. Escobar syndrome is character-
ized by short stature, pterygia of the neck, axilla, antecu-
bital, popliteal, digital, and intercrural areas, multiple
joint contractures and cleft palate [4]. Dimples at the
knees and other joints might be present. Facial features
include long face, downslanting palpebral fissures, ptosis,
long philtrum, emotionless face, low-set ears, high-
arched palate, small mouth, downturned corners of
mouth, inability to fully open mouth and retrognathism.
Skeletal anomalies such as fusion of cervical vertebrae,
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scoliosis, kyphosis, flexion contraction of fingers, rocker-
bottom feet with vertical talus may be present [5]. Small
penis and scrotum and cryptorchidism are seen in males.
Females might have aplasia of the labia majora and small
clitoris. Variable other features include intrauterine death,
congenital respiratory distress, reduced foetal movement,
and conductive hearing loss. Changing phenotype from
birth to childhood has been observed [6].
Autosomal recessive inheritance appears to be the
most common in MPS cases. However, the disease may
be transmitted as an autosomal dominant or X linked
trait [7–9]. Mutations in genes encoding different sub-
units of the nicotinergic acetylcholine receptor (AChR),
an excitatory cation channel, have been associated with
MPS. In humans, muscle-specific AChR is a transmem-
brane pentameric glycoprotein composed of four differ-
ent subunits, two α subunits, one β, one δ and one γ/ε
subunit, encoded by CHRNA1, CHRNB, CHRND and
CHRNG/CHRNE, respectively. The AChR exists in two
forms, the embryonic form, present in foetal and dener-
vated muscle and the adult form, which is predomin-
antly expressed postnatal [10, 11]. In humans, the switch
from the embryonic AChR to the adult is apparently
completed by the 33st week of gestation, in the late
foetal and perinatal period [12]. The γ subunit of AChR
(CHRNG) is expressed during early foetal development,
whereas in the adult it is replaced by a ε subunit
(CHRNE). Each AChR subunit comprises a large extra-
cellular glycosylated N-terminal ligand-binding domain,
followed by three hydrophobic transmembrane regions,
which form the ionic channel, followed by an intracellu-
lar region of variable length. A fourth hydrophobic
transmembrane region is located at the C-terminal
domain.
Hereditary congenital myasthenic syndrome (OMIM
608931, 608930, 601462 and 254210) is predominantly
caused by mutations in CHRNA1, CHRNB1, CHRND and
CHRNE, the genes encoding α, β, δ and ε AChR subunits,
respectively [13]. While mutations in the gene encoding
the gamma subunit of the AChR (CHRNG), cause most
cases of EVMPS and a smaller percentage of cases of
LMPS, homozygous nonsense mutations in CHRNA1
and CHRND, are associated with LMPS [4, 14–17].
Whole-Exome Sequencing (WES) was applied in 9
Iranian cases (2 foetuses and 7 children) with clinical
presentation of arthrogryposis. In 4 cases CHRNG was
suspected as the most likely gene underlying the disease
and the association of CHRNG with the disease was
confirmed in three out of four cases. Here, we report
one novel and two previously reported deletions of two
nucleotides in CHRNG, causing a frameshift predicted to
result in premature termination of the foetally expressed
gamma subunit of the AChR in three families of Iranian
descent with EVMPS. We also emphasize the changing
phenotype from infancy to childhood and intrafamilial
variability.
Cases
In family 1 (Fig. 1a), a female (IV:3) was born to healthy
consanguineous (first-cousin) parents of Iranian descent.
The mother had history of two spontaneous abortions at
6 weeks and 7 weeks of gestation. Pregnancy was un-
eventful. Amniocentesis was performed because of high
risk of trisomy 21 in the first trimester screening.
Chromosomal study was normal. Elective cesarean sec-
tion was performed at term. At birth, her weight was
2800 g (10th centile), and her length and head circumfer-
ence were 44 cm (<3rd centile) and 35 cm (50th centile),
respectively. Physical examination at 1 month of age
disclosed a very short neck, mild pterygia in the axillae,
elbows and knees, contracture of joints (elbows, wrists,
fingers, knees and ankles) clenched hands with thumbs
held across palm and club feet (varus). The elbows and
knees were held in flexed position and had limitation of
movement (Fig. 2a, b). She had rockerbottom feet, with
almost no movement in ankles (Fig. 2c). Facial dys-
morphism included hemangioma over forehead and
nose, strabismus, flat nasal bridge, downturned corners
of mouth. Whole body X-rays did not show major
abnormality.
In family 2 (Fig. 1b), individual II:1 was the first and
only child of a unrelated couple. The mother noted re-
duced foetal movement during pregnancy. Delivery was
at 39 weeks of gestation by cesarean section because of
breech position. Birth weight, length and head circum-
ference were 3150 g (<50th centile), 43 cm (<3rd centile)
and 36 cm (75th centile), respectively. When assessed at
two and a half months, her weight was 4500 g (<10th
centile), height 53 cm (<3rd centile) and head circumfer-
ence 41.5 cm (<75th centile). Multiple joint contractures
in the neck (torticolli), shoulders, elbows, wrist, fingers,
knees and halluces were noted (Fig. 2d). The hands were
clenched and thumb held across palm. The shoulders
were rounded, sloping and decreased in muscle mass.
There was dimpling in the elbows (Fig. 2e). Pterygium
was noted in the axillary region. She had a capillary
hemangioma on nasal nip and forehead, and micro-
gnathia in the face (Fig. 2f ). Full body X-ray showed
scoliosis. Echocardiography was normal. Ultra-sound
examination of the brain, abdomen (liver, gall bladder,
pancreas and spleen), kidneys and hip joint appeared
normal.
In family 3 (Fig. 1c), individual IV:3 was born to first-
cousin parents of Iranian descent. The first pregnancy
was a boy (IV:1) with multiple contractures and pteryg-
ium in joints, who died at the age of 6 months. The sec-
ond pregnancy was a twin pregnancy, the proband (IV:3)
and a similarly affected boy (IV:2) who died at the age of
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1.5 years. The third pregnancy resulted in intra-uterine-
foetal death at 20 weeks of gestation (IV:4). Delivery was
by caesarean section at 9 months of pregnancy. Birth
weight was 2500 g (5th centile). Pterygium in knees and
elbows was noticed from birth. The infant had multiple
episode of epistaxis, which led to the diagnosis of von
Willebrand type III hemophilia. Milestones were de-
layed; he held his head at age 1 year, he stood at 2 years
of age, and walked at age 2.5 years. Cognition was nor-
mal and he started saying words at age 10 months and
Fig. 1 Pedigrees for families included in this study. Affected individuals are represented with shaded symbols and probands are indicated with an
arrow. Identified mutation is indicated in each family
Fig. 2 Clinical features of subjects with CHRNG mutations and non-lethal variant of MPS. Case IV:1 from family 1, demonstrates a very short neck,
mild pterygia in the axillae, elbows and knees, contracture of joints, clenched hands with thumbs held across palm and club feet, at 1 month of
age. The elbows and knees were held in flexed position and had limitation of movement (a and b). She had rockerbottom feet (c). In family 2,
individual II:1 has multiple joint contractures in the neck, shoulders, elbows, wrist, fingers, knees and halluces were noted (d) and dimpling in the
elbows (e). She has a capillary hemangioma on nasal nip and forehead, and micrognathia in the face (f). In family 3, individual IV:3 at the age of
7 years demonstrates facial dysmorphism including posterior and anterior low hairline, down-slanting palpebral fissures, epicanthal folds, broad
nose, high nasal bridge, long philtrum, high-arched palate, rockerbottom feet, and micrognathia (g). He has camtodactyly of all fingers and skin
syndactyly of fingers (h) and the teeth are small and malpositioned (i). The micropenis is apparent (j)
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he had normal speech at 7 years of age. Bilateral inguinal
hernia was treated surgically at the age of 3 years old. At
7 years of age, his height, weight and head circumference
were 117 cm (<25th centile), 16 kg (<3rd centile) and
49.5 cm (<50th centile), respectively. Detailed review at the
age of 7 years revealed facial dysmorphism including pos-
terior and anterior low hairline, down-slanting palpebral
fissures, epicanthal folds, broad nose, high nasal bridge,
long philtrum, high-arched palate, and micrognathia
(Fig. 2g). The teeth were small and malpositioned (Fig. 2i).
Pterygia were present in neck, axillae, antecubital and in
intercrural region. Contracture at elbows, limitation of
elbow extension, limited movement of flexion and exten-
sion in wrists, camtodactyly of all fingers and skin syndac-
tyly of fingers, rockerbottom feet, and second toe
overlapping first and third in both feet, limited move-
ment in ankles, limited flexion and extension of knees
and micropenis were apparent (Fig. 2g, h, j). Intellectual
development appeared normal. Clinical features in the
investigated families are summarised in Table 1.
Methods
DNA isolation
Blood samples were collected from probands, parents
and siblings. Extraction of genomic DNA was performed
from whole blood from patients and parents, using
DNeasy Blood & Tissue kit (Qiagen, Hilden Germany),
according to the manufacturer’s instructions. In addition,
genomic DNA was extracted from 120 Iranian blood
donors, who served as controls.
Genetic analysis
Exome sequence analysis
The WES was performed on DNA from patients and their
unaffected parents, as previously described [18]. Briefly,
target enrichment was performed with 3 μg genomic
DNA using the Sure SelectXT Human All Exon kit ver-
sion 5 (Agilent Technologies, Santa Clara, CA, USA) to
generate barcoded whole-exome sequencing libraries.
Libraries were sequenced on the HiSeq2000 platform
(Illumina, San Diego, CA, USA) as paired-end 2 × 100-bp
reads with 60x coverage. Quality assessment of the se-
quence reads was performed by generating QC statistics
with FastQC (http://www.bioinformatics.bbsrc.ac.uk/pro-
jects/fastqc). Read alignment to the reference human gen-
ome (hg19, UCSC assembly, February 2009) was done
using BWA [19] with default parameters. After removal of
polymerase chain reaction (PCR) duplicates (Picard tools,
http://picard.sourceforge.net) and file conversion (sam-
tools [20]) quality score recalibration, indel realignment
and variant calling were performed with the Haplotype-
Caller algorithm in the GATK package [21] based on
established best practices [22].
Variant annotation and selection
Variants were annotated with ANNOVAR [23] using a
wide range of databases such as dbSNP build 135,
dbNSFP, KEGG, the Gene Ontology project and tracks
from the UCSC. A filtering strategy, directed to disease
gene candidates, was performed by QIAGEN’s Ingenuity®
Variant Analysis™ software (www.qiagen.com/ingenuity)
from QIAGEN Redwood City. We focused on exonic
















Sex F F M
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examination
1 month 2.5 months 7 years




Pterygium axilla + + +
Pterygium elbows + - +
Pterygium knees + - +
Camptodactyly + + +
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Hearing loss NE NE -
Cryptorchidism - - +
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variants where the mutation produced a missense
change, stop gain or stop loss. We required at least two
mutations in the same gene for further analysis. Only
those changes that were predicted to be damaging or
with unknown impact were kept. We excluded SNPs
that were shared with our control dataset (>1 % in
dbSNP [24], the Exome Variant Server (NHLBI)(http://
evs.gs.washington.edu/EVS/), the 1000 Genome Project
Database and the human Background Variant Database
(http://neotek.scilifelab.se/hbvdb/)) as well as those labeled
as compound heterozygous.
Polymerase chain reaction (PCR) and Sanger sequencing
The variants found by WES in the candidate genes were
examined in the individuals by PCR and Sanger sequen-
cing using an ABI 3730XL (GATC Biotech, Constance,
Germany and Eurofins MWG Operon, Ebersberg,
Germany) if they had either a variant frequency <1 % in
the healthy population or a minor allele frequency
(MAF) below the normal MAF in the European popula-
tion in EVS. PCR was performed on DNA samples from




Data from WES on DNA from patients and their parents
were analysed through the use of the Ingenuity Variant
Analysis (IVA) software (Qiagen, Hilden Germany). The
filtering strategy narrowed the starting variants to 16, 11
and 12 genes in case IV:3 (family 1), II:1 (family 2) and
IV:3 (family 3), respectively. This approach allowed the
identification of homozygous deletion of two nucleotides
in exons of CHRNG in these cases. All other related
disease-causing genes were excluded in these cases. We
identified a novel homozygous deletion of two nucleo-
tides in exon 9 (c.1009-1010delCA) (ID SUB1128405) of
CHRNG in case IV:3 of family 1, leading to a frameshift
predicted to result in premature termination (p.His337f-
s60Ter) (Fig. 3). In case II:1 of family 2, the filtering
strategy narrowed the variants to 11 genes, including a
homozygous previously reported deletion of two nucleo-
tides in exon 7 (c.753-754delCT) of CHRNG, leading to a
frameshift predicted to result in a premature termination
(p.Val253fs44Ter) (Fig. 3). In case IV:3 of family 3, a
previously reported homozygous deletion of two nucle-
otides in exon 5 (c.401-402delCT) of CHRNG was iden-
tified, leading to a frameshift. The c.401-402delCT
mutation was predicted to result in premature termin-
ation (p.Pro134fs43Ter) (Fig. 3).
Putative deleterious variants in CHRNG exons 5, 7 and
9, were confirmed in the children and their parents by
PCR and Sanger sequencing analysis. The unaffected par-
ents were heterozygous for the two nucleotide deletions.
None of the mutations was reported in public databases
as a polymorphism. However, in order to define the fre-
quency of the identified variants in population-matched
controls, PCR and Sanger sequencing of CHRNG exons 5,
7 and 9 was performed in 120 Iranian blood donors, who
served as controls. The results from sequencing analysis
excluded the CHRNG sequence variants in 120 Iranian
control individuals.
The recurrent homozygous deletion of two nucleotides
in exon 7 (c.753-754delCT) was identified in the only
child of a unrelated couple (in case II:1 of family 2).
Haplotyping was not available so it is not known if this
was due to a founder mutation. However, the percentage
of homozygosity in exome sequencing of this case com-
pared to two other probands born to the first-cousin
parents was notably lower (5.6 %).
Discussion
The mammalian muscle-specific acetylcholine receptor
is a transmembrane glycoprotein with two alpha, one
beta, one delta and one gamma (expressed in foetal and
denervated muscle) or epsilon (expressed in adult skel-
etal muscle) subunit [12]. The gamma subunit of AChR,
encoded by CHRNG, is expressed prior to the thirty-
third week of gestation in humans [10, 25, 26]. It helps
to establish the primary encounter of muscle and axon
and has thus, a pivotal role in neuromuscular organo-
genesis and ligand binding [27]. Mutations in gamma
subunits cause MPS, either the severe and fatal form
(LMPS), or the milder and non-lethal Escobar variant [4,
14, 15]. Previous study has demonstrated that disruption
of gamma subunit expression prevents the correct
localization of the receptor in cell membranes [14]. The
ultimate result of the impaired γ subunit structure is
Fig. 3 CHRNG mutations in the investigated families with EVMPS
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reduced prenatal muscle strength and movement, explain-
ing the contractures and pterygia [14].
Here, we report three families with EVMPS associated
with one novel and two previously reported frameshift
mutations in CHRNG. These mutations are anticipated
to result in premature mRNA nonsense-mediated decay
followed by a γ subunit deficiency or predicted to result
in premature termination of transcription of the foetally
expressed gamma subunit of the AChR. All patients had
clinical features consistent with MPS Escobar variant,
including arthrogryposis multiplex congenita, multiple
pterygia, short stature and dysmorphic facial features,
corresponding to the developmental deformities in utero.
The novel homozygous deletion (c.1009-1010delCA;
p.His337fs60Ter) in family 1 is located in exon 9 of
CHRNG. In the absence of nonsense-mediated decay,
the mutation is predicted to result a frameshift followed
by a truncated gamma AChR subunit lacking intracellu-
lar region and the fourth hydrophobic transmembrane
domain. Consequently, the mutation will lead to a dys-
functional or deficient foetal AChR, which in turn will
cause impaired prenatal neuromuscular transmission
and organogenesis followed by developmental defects. It
is likely that this homozygous mutation caused the his-
tory of abortions in this family. Since the abortions oc-
curred very early in pregnancy (at 7 and 8 weeks of
gestation, respectively), the fetopathological examination
could not be performed and therefore, there are no fur-
ther clinical details. It is thus uncertain whether the
typical clinical features corresponding to the lethal
MPS were present in these cases.
The recurrent c.753-754delCT, pVal253Alafs44Ter
mutation identified in family 2 was previously reported
in patients from different ethnic backgrounds affected
with both the lethal and non-lethal phenotypes [15, 17].
It was found in the homozygous state and in combin-
ation with a second CHRNG heterozygous mutation.
The previously reported homozygous c.753-754delCT,
pVal253Alafs44Ter mutation was found in cases with
the lethal and non-lethal MPS, born to consanguineous
parents of Turkish descent [15, 17]. It was also found
together with a second CHRNG heterozygous mutation
in two compound heterozygous individuals with EVMPS
phenotype [15]. Thus, the c.753-754delCT mutation
may cause both lethal and non-lethal MPS, and the
homozygous state of the mutation is not decisive of the
lethal spectrum. Furthermore, there is no apparent cor-
relation between mutation position and clinical pheno-
type. Therefore, genetic background and interindividual
differences, and environmental modifiers might be of
significance.
As previously reported, severity of the phenotype var-
ies significantly both within and between families with
MPS [6, 15]. This is further supported in family 3, in
which the first and second siblings with non-lethal MPS
were severely affected and died in the early infancy.
However, it is unclear how the lethality in the two
affected siblings was influenced by the severity of the
congenital deformities. As previously suggested [15] the
chance of a non-lethal MPS phenotype arising in further
affected siblings within families associated with homozy-
gous c.401-402delCT; p.Pro134Argfs34Ter mutation is
more likely. The c.401-402delCT; p.Pro134Argfs34Ter
mutation was previously reported in a 14-year-old boy
with clinical features closely resembling individual IV:3
of family 3 [4]. Contracture and pterygia in all major
joints and facial features characteristic for Escobar syn-
drome was present in both cases. However, bilateral in-
guinal hernia and micropenis observed in our patient,
was not reported in the previous case. This homozygous
deletion mutation was further reported in an individual
with EVMPS phenotype born to a non-consanguineous
couple from the UK [15]. The frequently observed
CHRNG c.753-754delCT; pVal253Alafs44Ter and c.401-
402delCT; p.Pro134Argfs34Ter mutations indicate the
mutational hotspot of these residues [4, 15, 17].
It has been suggested that there is a high concordance
between siblings regarding the severity of clinical find-
ings in families with EVMPS [15]. However, the history
of increased frequency of abortions and stillbirth in re-
ported families with EVMPS [4, 14, 15] and the presence
of two abortions in family 1 and two perinatal deaths in
family 3 suggest that variable severity of disease could
exist in the same family.
Given the fact that CHRNG is expressed only during
early foetal development and in denervated cells and
that the γ subunit is not a component of the adult
acetylcholine receptor [10–12], postnatal muscle biopsy
from affected individuals with EVMPS phenotype is in-
applicable to assess the effect of CHRNG mutations on
transcripts and protein levels. Likewise, it is unlikely that
postnatal muscle biopsy discloses specific muscle histo-
pathology, as postnatal muscle weakness is not a feature
of CHRNG associated MPS Escobar variant. Although
myasthenic features and abnormal muscle histopath-
ology is not expected in patients with CHRNG muta-
tions, congenital diaphragmatic muscle weakness, diffuse
myopathy and myasthenic-like features have frequently
been reported in some patients [14]. This can be due to
the role of γ subunit AChR in muscle organogenesis.
Clinical examination of our patients indicates that the
complete clinical features of MPS Escobar variant
develop past infancy. This is supported by previous
study describing detail clinical features of individuals
with EVMPS [6]. While certain clinical features are not
present at birth and become apparent, as the infant
grows older, other features improve with time. For ex-
ample, the clear pterygia is not apparent in cases IV:3
Kariminejad et al. BMC Genetics  (2016) 17:71 Page 6 of 8
(family 1) and II:1 (family 2), at the age of one and two
and a half months, respectively, whereas it is completely
evident in case IV:3 (family 3), at the age of seven years.
Infants have the severe joint contractures and limited
movement at birth, which persists but might improve as
the child grows older. Many infants born with Escobar
syndrome have clenched hands with the thumb held
across the palm. However, they can open their fist and
have improvement of the position of the thumb as they
grow older [6]. Individuals IV:3 and II:1 in family 1 and
2, respectively, show clenched hands with the thumbs
held across thumb. Likewise, individual IV:3 in family 3
is said to have had the similar clinical finding at infancy.
However, this clinical condition has improved and he
only has camptodactyly at the age of 7 years. Moreover,
the characteristic facial appearance of Escobar syndrome
including down-slanting palpebral fissures, ptosis, long
philtrum, sad and emotionless face, observed in the
older child is not present in the infants with Escobar
syndrome. Facial features dominantly present at birth in-
clude epicanthal fold, low-set ears, and micrognathia.
Capillary hemangioma observed in individuals IV:3 and
II:1 in family 1 and 2, respectively, is additional clinical
feature that has been reported in infants with Escobar
syndrome, but it is absent in the older child with Esco-
bar syndrome. Taking together, accurate diagnosis and
prognosis require follow-up of infants presenting
multiple joint contractures or arthrogryposis multiplex
congenital at birth, as many of them develop the charac-
teristic features of Escobar syndrome MPS over the first
few years of life.
Conclusions
In conclusion, we present three families affected by non-
lethal MPS and a novel and two previously reported
homozygous frameshift truncated mutations in CHRNG
predicted to result in truncations. We suggest that there
is no apparent correlation between mutation position
and clinical phenotype. Our data suggest the changing
phenotype from infancy to childhood in individuals
affected by MPS Escobar variant and that severity of
the phenotype varies both within and between fam-
ilies with MPS.
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